Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (2517)	1/24/2011 8:27:23 AM
From: Steve Lokness	Respond to of 2557

Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) PDUFA Goal Date Designated as May 30, 2011 prnewswire SAN DIEGO, Jan. 24, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI. The FDA has also granted the Company's request for six-month Priority Review, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. Additionally, the FDA has informed us that it plans to discuss the NDA at a meeting of its Anti-Infective Drugs Advisory Committee currently scheduled for April 5, 2011. (Logo: photos.prnewswire.com The acceptance of the fidaxomicin NDA for filing confirms the FDA's determination that the NDA is sufficiently complete to permit a substantive review. A Priority Review classification is granted to drugs that, if approved, have the potential to provide significant improvements compared to marketed treatments, or provide a treatment where no satisfactory alternative therapy exists. A Priority Review means that the goal for the time it takes the FDA to review a new drug application is reduced. Based on this classification, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011 for its review of the NDA. "In Phase 3 clinical trials, fidaxomicin not only showed a high clinical cure rate, but also demonstrated a statistically significant improvement in reducing recurrences, one of the major problems in the current management of CDI," said Pedro Lichtinger, Optimer's President and CEO. "The agency's acceptance of our NDA represents a step forward to fulfill an unmet medical need and supports our goal of helping patients who are suffering from this disease." The NDA is supported by data from the two largest comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. The two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult patients. Patients with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. In both of these studies, fidaxomicin met the primary endpoint of non-inferiority of clinical cure compared to Vancocin. Importantly, in both trials fidaxomicin was statistically superior to Vancocin in reducing recurrences of CDI and in global cure rate. finance.yahoo.com